Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules.

Autor: Nabet B; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. behnam_nabet@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. behnam_nabet@dfci.harvard.edu., Ferguson FM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Seong BKA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kuljanin M; Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Leggett AL; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Mohardt ML; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Robichaud A; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Conway AS; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Buckley DL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Mancias JD; Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bradner JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. nathanael_gray@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. nathanael_gray@dfci.harvard.edu.

Publikováno v: Nature communications [Nat Commun] 2020 Sep 18; Vol. 11 (1), pp. 4687. Date of Electronic Publication: 2020 Sep 18.

Discovery of a selective inhibitor of doublecortin like kinase 1.

Autor: Ferguson FM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Nabet B; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Raghavan S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Liu Y; Departments of Biochemistry and Radiation Oncology, the University of Texas Southwestern Medical Center, Dallas, TX, USA., Leggett AL; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Kuljanin M; Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kalekar RL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Yang A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., He S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Ng RWS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sulahian R; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Li L; Departments of Biochemistry and Radiation Oncology, the University of Texas Southwestern Medical Center, Dallas, TX, USA., Poulin EJ; Cancer Research Institute and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Huang L; Cancer Research Institute and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Koren J; Department of Molecular and Human Genetics, Therapeutic Innovation Center Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA., Dieguez-Martinez N; Departament de Bioquímica i Biologia Molecular & Institut de Neurociencies, Facultat de Medicina. Universitat Autonoma de Barcelona, Bellaterra, Spain., Espinosa S; Departament de Bioquímica i Biologia Molecular & Institut de Neurociencies, Facultat de Medicina. Universitat Autonoma de Barcelona, Bellaterra, Spain., Zeng Z; Promega Corporation, Madison, WI, USA., Corona CR; Promega Corporation, Madison, WI, USA., Vasta JD; Promega Corporation, Madison, WI, USA., Ohi R; Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA., Sim T; Chemical Kinomics Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea and KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, Republic of Korea., Kim ND; NDBio Therapeutics Inc, Incheon, Republic of Korea., Harshbarger W; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; GSK Vaccines, Rockville, MD, USA., Lizcano JM; Departament de Bioquímica i Biologia Molecular & Institut de Neurociencies, Facultat de Medicina. Universitat Autonoma de Barcelona, Bellaterra, Spain., Robers MB; Promega Corporation, Madison, WI, USA., Muthaswamy S; Cancer Research Institute and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Departments of Medicine and Pathology, Harvard Medical School, Boston, MA, USA., Lin CY; Department of Molecular and Human Genetics, Therapeutic Innovation Center Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA., Look AT; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA., Haigis KM; Cancer Research Institute and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Harvard Digestive Disease Center, Harvard Medical School, Boston, MA, USA., Mancias JD; Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Westover KD; Departments of Biochemistry and Radiation Oncology, the University of Texas Southwestern Medical Center, Dallas, TX, USA., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. nathanael_gray@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. nathanael_gray@dfci.harvard.edu.

Publikováno v: Nature chemical biology [Nat Chem Biol] 2020 Jun; Vol. 16 (6), pp. 635-643. Date of Electronic Publication: 2020 Apr 06.

The dTAG system for immediate and target-specific protein degradation.

Autor: Nabet B; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Roberts JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Buckley DL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Paulk J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Dastjerdi S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Yang A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Leggett AL; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Erb MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lawlor MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Souza A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Scott TG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Vittori S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Perry JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Qi J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Winter GE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; CeMM- Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Wong KK; Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USA., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. nathanael_gray@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. nathanael_gray@dfci.harvard.edu., Bradner JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. james.bradner@novartis.com.; Department of Medicine, Harvard Medical School, Boston, MA, USA. james.bradner@novartis.com.; Novartis Institutes for BioMedical Research, Cambridge, MA, USA. james.bradner@novartis.com.

Publikováno v: Nature chemical biology [Nat Chem Biol] 2018 May; Vol. 14 (5), pp. 431-441. Date of Electronic Publication: 2018 Mar 26.

Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.

Autor: Rusan M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts., Li K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea., Li Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts., Christensen CL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Abraham BJ; Whitehead Institute for Biomedical Research, Cambridge, Massachusetts., Kwiatkowski N; Whitehead Institute for Biomedical Research, Cambridge, Massachusetts.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Buczkowski KA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Bockorny B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts.; Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts., Chen T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Li S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Rhee K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Zhang H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Chen W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Terai H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Tavares T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Leggett AL; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Li T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Wang Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Zhang T; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Kim TJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea., Hong SH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Poudel-Neupane N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Silkes M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Mudianto T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Tan L; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Shimamura T; Molecular Pharmacology and Therapeutics, Oncology Research Institute, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois., Meyerson M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts., Bass AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts.; Departments of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts., Watanabe H; Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Young RA; Whitehead Institute for Biomedical Research, Cambridge, Massachusetts.; Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts., Wong KK; Laura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York., Hammerman PS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. peter.hammerman@novartis.com.; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts.; Novartis Institutes of Biomedical Research, Cambridge, Massachusetts.

Publikováno v: Cancer discovery [Cancer Discov] 2018 Jan; Vol. 8 (1), pp. 59-73. Date of Electronic Publication: 2017 Oct 20.